Cargando…
Biosimilars and biologics : implementation and monitoring in a healthcare setting /
Get Up to Speed on the Fastest Growing Pharmaceutical Innovation With the Only Guide Written for Pharmacists Among the most anticipated and discussed segments of the pharmaceutical market, biosimilars, are finally beginning to exert a greater impact on practice. To meet the growing need for informat...
| Clasificación: | Libro Electrónico |
|---|---|
| Autor principal: | |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Bethesda, MD :
American Society of Health-System Pharmacists, Inc.,
[2018]
|
| Temas: | |
| Acceso en línea: | Texto completo |
MARC
| LEADER | 00000cam a2200000 i 4500 | ||
|---|---|---|---|
| 001 | EBOOKCENTRAL_on1039079127 | ||
| 003 | OCoLC | ||
| 005 | 20240329122006.0 | ||
| 006 | m o d | ||
| 007 | cr cnu---unuuu | ||
| 008 | 180607s2018 mdu ob 001 0 eng d | ||
| 040 | |a N$T |b eng |e rda |e pn |c N$T |d OCLCO |d YDX |d EBLCP |d MERUC |d N$T |d UAB |d OCLCF |d OCLCQ |d DKU |d OCLCO |d OCLCA |d OCLCQ |d K6U |d OCLCA |d OCLCQ |d OCLCO |d LUU |d OCLCQ |d OCLCO |d OCLCL | ||
| 020 | |a 9781585285815 |q (electronic bk.) | ||
| 020 | |a 1585285811 |q (electronic bk.) | ||
| 020 | |z 9781585285808 | ||
| 020 | |z 1585285803 | ||
| 035 | |a (OCoLC)1039079127 | ||
| 050 | 4 | |a RS380 | |
| 060 | 1 | 0 | |a QV 241 |
| 072 | 7 | |a MED |x 071000 |2 bisacsh | |
| 082 | 0 | 4 | |a 615.1/9 |2 23 |
| 049 | |a UAMI | ||
| 100 | 1 | |a Lucio, Steven, |e author. | |
| 245 | 1 | 0 | |a Biosimilars and biologics : |b implementation and monitoring in a healthcare setting / |c Steven Lucio. |
| 264 | 1 | |a Bethesda, MD : |b American Society of Health-System Pharmacists, Inc., |c [2018] | |
| 264 | 4 | |c ©2018 | |
| 300 | |a 1 online resource | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 504 | |a Includes bibliographical references and index. | ||
| 505 | 0 | |a A new type of blockbuster : the growth of biologics -- Déjá vu or something new? : comparing the generics and biosimilars experiences -- Bugs and drugs, and yeast and mice, and Chinese hamsters -- The $250 billion pyramid : analytics in biosimilarity determination -- The global biosimilars experience -- The American biosimilar experience : red, white, and possibly interchangeable -- Biosimilar clinical trial requirements -- Immunogenicity and pharmacovigilance in the biosimilar era -- The patent dance and the exclusivity shuffle -- Defining biosimilar value and other impossible tasks -- Biosimilar formulary management strategies. | |
| 588 | 0 | |a Online resource; title from PDF title page (EBSCO, viewed August 8, 2018). | |
| 520 | |a Get Up to Speed on the Fastest Growing Pharmaceutical Innovation With the Only Guide Written for Pharmacists Among the most anticipated and discussed segments of the pharmaceutical market, biosimilars, are finally beginning to exert a greater impact on practice. To meet the growing need for information, ASHP has published Biosimilars and Biologics. This authoritative, evidence-based resource provides an in-depth perspective on all areas related to these innovative drugs, including: · Legislative/regulatory issues, including the biosimilars act and anticipated FDA guidelines · | ||
| 590 | |a ProQuest Ebook Central |b Ebook Central Academic Complete | ||
| 590 | |a eBooks on EBSCOhost |b EBSCO eBook Subscription Academic Collection - Worldwide | ||
| 650 | 0 | |a Pharmaceutical biotechnology. | |
| 650 | 0 | |a Pharmaceutical biotechnology industry. | |
| 650 | 0 | |a Drugs |x Generic substitution. | |
| 650 | 0 | |a Pharmaceutical policy. | |
| 650 | 0 | |a Biological products. | |
| 650 | 2 | |a Biosimilar Pharmaceuticals | |
| 650 | 2 | |a Drug Compounding | |
| 650 | 2 | |a Drug Monitoring | |
| 650 | 2 | |a Biological Factors | |
| 650 | 6 | |a Biotechnologie pharmaceutique. | |
| 650 | 6 | |a Biotechnologie pharmaceutique |x Industrie. | |
| 650 | 6 | |a Médicaments |x Dénomination commune. | |
| 650 | 6 | |a Médicaments |x Politique gouvernementale. | |
| 650 | 6 | |a Produits biologiques. | |
| 650 | 6 | |a Médicaments biosimilaires. | |
| 650 | 6 | |a Pharmacovigilance. | |
| 650 | 7 | |a MEDICAL |x Pharmacology. |2 bisacsh | |
| 650 | 7 | |a Biological products |2 fast | |
| 650 | 7 | |a Drugs |x Generic substitution |2 fast | |
| 650 | 7 | |a Pharmaceutical biotechnology |2 fast | |
| 650 | 7 | |a Pharmaceutical biotechnology industry |2 fast | |
| 650 | 7 | |a Pharmaceutical policy |2 fast | |
| 758 | |i has work: |a Biosimilars and biologics (Text) |1 https://id.oclc.org/worldcat/entity/E39PCFxRGbRRYQwHhdGftDmkMq |4 https://id.oclc.org/worldcat/ontology/hasWork | ||
| 856 | 4 | 0 | |u https://ebookcentral.uam.elogim.com/lib/uam-ebooks/detail.action?docID=5412768 |z Texto completo |
| 938 | |a EBL - Ebook Library |b EBLB |n EBL5412768 | ||
| 938 | |a EBSCOhost |b EBSC |n 1825168 | ||
| 938 | |a YBP Library Services |b YANK |n 15498940 | ||
| 994 | |a 92 |b IZTAP | ||